A Phase 1 in Patients With HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers
← catalyst calendarSponsored by Cue Biopharma (industry) · CUE — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
42actual
Sites
15
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-06-14 | actual | When the study began enrolling |
| Primary completion | 2025-03-12 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-03-12 | actual | The whole study's end, after follow-up |
| First posted | 2022-05-04 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-01-22 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Colorectal Cancer
- Gastric Cancer
- Pancreatic Cancer
- Ovarian Cancer
Intervention
- Drug: CUE-102
Primary outcomes
what the primary-completion date above is the date OFDose Limiting Toxicity
measured 21 Days
Maximum Tolerated Dose
measured 21 Days
Serum PK AUC for CUE-102
measured Up to 2 years
Serum PK Cmax for CUE-102
measured Up to 2 years
Serum PK T1/2 for CUE-102
measured Up to 2 years
Permalink · CUE's whole pipeline · Catalyst calendar · Every registered study · What changed